{
    "clinical_study": {
        "@rank": "88993", 
        "acronym": "MYLY", 
        "arm_group": {
            "arm_group_label": "MYOCET", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The protocol is to assess the overall response rate (complete response and partial response)\n      of treatment with non-pegylated liposomal doxorubicin at a dose of 50 mg / m\u00b2 in combination\n      with dexamethasone in immunocompetent adult patients with primary brain lymphoma large\n      B-cell refractory or relapsed after first-line treatment MTXHD and high-dose cytarabine,\n      excluding strict eye lymphomas.\n\n      This is a Phase II, open, prospective, multicenter, non-comparative with direct individual\n      benefit."
        }, 
        "brief_title": "Phase II Study Evaluating a Combination of Pegylated Liposomal Doxorubicin and Dexamethasone for the Treatment of Immunocompetent Patients With Cerebral Lymphoma Relapsed or Refractory to First-line Chemotherapy With High Dose Methotrexate (MTXHD) and / or High-dose Cytarabine.", 
        "completion_date": {
            "#text": "June 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Cerebral Lymphoma B Cell Refractory", 
        "condition_browse": {
            "mesh_term": [
                "Lymphoma", 
                "Lymphoma, B-Cell"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patient with cerebral lymphoma B cell refractory or relapsed within 12 months after\n             first-line chemotherapy with high-dose methotrexate (1.5 g / m\u00b2) and high dose\n             cytarabine (2g / m\u00b2) and / or radiotherapy or autologous, or patient with an\n             indication against these treatments.\n\n        Refractory disease is defined by the absence of objective response to treatment or relapse\n        within 3 months of it. A relapse is defined as disease progression after obtaining a\n        complete or partial response.\n\n          -  Age greater than or equal to 18 years\n\n          -  Performance Index less than 4\n\n          -  Illness measured by CT or MRI\n\n          -  Hematologic adequate: neutrophils> 1.5 x 106 / L, platelets> 100x106 / L\n\n          -  Adequate hepatic function: ALT / AST and bilirubin less than the upper limit of the\n             normal laboratory\n\n          -  Adequate renal function: creatinine clearance greater than 60 ml / min\n\n          -  adequate cardiac function measured by ejection fraction of the left ventricle> 50% by\n             echocardiography\n\n          -  Informed consent signed\n\n          -  Negative pregnancy test for women of childbearing age\n\n          -  Able to understand the arrangements for monitoring the study and to comply\n\n          -  Corticosteroids are only accepted during the first cycle\n\n        Exclusion Criteria:\n\n          -  Patients with immunosuppression from any cause (HIV, history of transplantation,\n             immunosuppressive treatments ...)\n\n          -  Prior treatment MYOCET \u00ae or other anthracycline\n\n          -  Active infection\n\n          -  Surgery large (more than 3 days hospitalization) within 28 days before enrollment in\n             the study, except for a diagnostic neurosurgical\n\n          -  Hypersensitivity to any component of the treatment\n\n          -  Contraindications to the administration of MYOCET \u00ae and / or dexamethasone\n             Participation in a clinical trial within 4 weeks prior to study entry"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "25", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 3, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01848652", 
            "org_study_id": "RB 12.032 - MYLY"
        }, 
        "intervention": {
            "arm_group_label": "MYOCET", 
            "intervention_name": "infusion of MYOCET", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Cytarabine", 
                "Methotrexate", 
                "Dexamethasone", 
                "Doxorubicin", 
                "Dexamethasone acetate", 
                "Dexamethasone 21-phosphate", 
                "BB 1101"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "cerebral lymphoma B cell refractory", 
            "Myocet", 
            "efficacy", 
            "safety"
        ], 
        "lastchanged_date": "March 31, 2014", 
        "location": [
            {
                "contact": {
                    "last_name": "Krimo BOUABDALLAH, Dr"
                }, 
                "facility": {
                    "address": {
                        "city": "Bordeaux", 
                        "country": "France", 
                        "state": "Pessac", 
                        "zip": "33604"
                    }, 
                    "name": "Groupe Hospitalier Sud - H\u00f4pital Haut-Lev\u00eaque Centre Fran\u00e7ois Magendie"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "adrian.tempescul@chu-brest.fr", 
                    "last_name": "Adrian TEMPESCUL, Dr", 
                    "phone": "02 98 22 33 95"
                }, 
                "facility": {
                    "address": {
                        "city": "Brest", 
                        "country": "France", 
                        "zip": "29609"
                    }, 
                    "name": "CHRU de Brest"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Le Mans", 
                        "country": "France", 
                        "zip": "72000"
                    }, 
                    "name": "CH du Mans"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "contact": {
                    "last_name": "franck MORSCHHAUSER, Dr"
                }, 
                "facility": {
                    "address": {
                        "city": "Lille", 
                        "country": "France", 
                        "zip": "59037"
                    }, 
                    "name": "H\u00f4pital Claude Huriez"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Caroline HOUILLER, Dr"
                }, 
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France", 
                        "zip": "75651"
                    }, 
                    "name": "H\u00f4pital Piti\u00e9 Salp\u00eatri\u00e8re"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rennes", 
                        "country": "France", 
                        "zip": "35033"
                    }, 
                    "name": "CHU de Rennes H\u00f4pital Pontchaillou"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tours", 
                        "country": "France", 
                        "zip": "37000"
                    }, 
                    "name": "CHU Tours Bretonneau"
                }, 
                "status": "Active, not recruiting"
            }
        ], 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase II Study Evaluating the Combination Pegylated Liposomal Doxorubicin and Dexamethasone for the Treatment of Immunocompetent Patients With Cerebral Lymphoma Relapsed or Refractory to First-line Chemotherapy Containing High Dose Methotrexate (MTXHD) and / or High-dose Cytarabine.", 
        "overall_contact": {
            "email": "adrian.tempescul@chu-brest.fr", 
            "last_name": "Adrian TEMPESCUL, Dr", 
            "phone": "02 98 22 33 95"
        }, 
        "overall_official": {
            "affiliation": "University hospital of Brest", 
            "last_name": "Adrian TEMPESCUL, Dr", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Answer, whether complete or partial, according to the International Primary CNS Lymphoma Collaborative Group (IPCG) (ASH 2004) after two cycles of treatment (4 infusions MYOCET \u00ae).", 
            "measure": "Answer at treatment", 
            "safety_issue": "Yes", 
            "time_frame": "after 2 cycles of treatment (84 days)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01848652"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Tolerance, assessed according to the criteria of the National Cancer Institute (NCI)-Common Toxicity Criteria (CTC) version (version 4.03) after administration of each cycle, overall survival, progression-free and disease-free event for complete responses.", 
            "measure": "Tolerance at treatment", 
            "safety_issue": "Yes", 
            "time_frame": "after each cycle and until the end of follow"
        }, 
        "source": "University Hospital, Brest", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University Hospital, Brest", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}